Yes - my bad - animal studies last year, feasibility this year at Melbourne and John Hunter Hospitals (with 40 patients/10 controls) and planned pivotal next year - with anticipated regulatory approvals and soft launch in 2027.
So, in terms of their, targets, they are a year behind us.
But I would think more likely at least 2 years as their 2027 soft launch target appears ambitious - given how long we now know these processes take - and will likely blow out just like our long anticipated 2025 commercial launch has.
I note that the competition is only with EMU - they don't have a 'first responder'.
A bit of competition doesn't worry me. It is a big market and we will have first mover advantage and a top shelf partner in Keysight who, no doubt, will be able to open many doors in the USA. They have a large stake in EMV's success - in terms of both shareholding and VNA sales.
EMV Price at posting:
$1.84 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)